Log in
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 


SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Catalent : Technologies to Enhance Cell Line Productivity and Expand Antibody-Drug Conjugate Therapeutic Window to be presented by Catalent Biologics at PEGS

08/26/2020 | 04:33am EDT

SOMERSET - Catalent, the leading global provider of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, cell and gene therapies, and consumer health products, today announced that two Catalent Biologics experts will present at the upcoming 16th Annual PEGS Boston Virtual Conference & Expo, taking place between Aug. 31 - September 4, 2020.

On Wednesday, Sept. 2 at 9:45 a.m. EDT, Gregory Bleck, Ph.D., Global Head of R&D, Catalent Biologics, will present 'GPEx Boost - A Novel Approach for High-Expressing CHO Cell Line Engineering' during the 'Optimizing Protein Expression' stream. Dr. Bleck will explain how the next generation of Catalent's GPEx cell line development technology can result in highly specific productivities, titers, and improved cell growth characteristics for most protein products.

Also on Wednesday, at 3:05 p.m. EDT, during the 'Engineering Antibody-Drug Conjugates' stream, Robyn Barfield, Ph.D., Group Leader, Catalent Biologics, will discuss Catalent's proprietary SMARTag technology, which uses a simple, robust manufacturing process to generate stable, site-specific antibody-drug conjugates (ADCs). In her presentation, titled 'Novel SMARTag Linkers Enable Better-Tolerated ADCs,' Dr. Barfield will discuss how the technology can offer wider therapeutic windows, illustrated through a comparison between Catalent's anti-HER2 RED-106 ADC, and the related drug, T-DM1.

During the virtual event, Dr. Barfield will also present the case study in her presentation as a poster, 'A Novel HER2-Targeted Antibody-Drug Conjugate Offers the Possibility of Clinical Dosing at Trastuzumab-Equivalent Exposure Levels.'

Dr. Bleck has more than 20 years of experience in biopharmaceutical research and development. He has a bachelor's degree and doctorate from the University of Wisconsin-Madison and performed postdoctoral work at the University of Illinois-Urbana-Champaign, working in the areas of gene regulation and expression. At Catalent, Dr. Bleck has transferred his knowledge of gene expression and transgenic systems to the development and continued optimization of retrovector expression systems and development of the proprietary GPEx process.

Dr. Barfield has more than 10 years' experience working in bioconjugation, and joined Catalent Biologics when it acquired Redwood Bioscience in 2014. She has a doctorate in cell and molecular biology from the University of Pennsylvania School of Medicine and a bachelor's degree in genetics and cell biology, from the University of Georgia.

The event's presentations and panel discussions will be available to view on-demand through the conference platform.

Catalent, GPEx and SMARTag are registered trademarks of Catalent, Inc. or its affiliates or subsidiaries.


Catalent Biologics is a global leader in development, manufacturing and analytical services for new biological entities, cell and gene therapies, biosimilars, sterile injectables, and antibody-drug conjugates. With over 20 years of proven expertise, Catalent Biologics has worked with 600+ mAbs and 80+ proteins, produced 13 biopharmaceutical drugs using GPEx cell line development technology, and manufactured 35+ commercially approved products. Catalent Cell & Gene Therapy, a unit of Catalent Biologics, is a full-service partner for adeno-associated virus (AAV) vectors and CAR-T immunotherapies, with deep experience in viral vector scale-up and production. Catalent recently acquired MaSTherCell, adding expertise in autologous and allogeneic cell therapy development and manufacturing. Catalent Cell & Gene Therapy has produced 100+ cGMP batches across 70+ clinical and commercial programs.


Catalent is the leading global provider of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, cell and gene therapies, and consumer health products. With over 85 years serving the industry, Catalent has proven expertise in bringing more customer products to market faster, enhancing product performance and ensuring reliable global clinical and commercial product supply. Catalent employs over 13,500 people, including over 2,400 scientists and technicians, at more than 40 facilities, and in fiscal year 2019 generated over $2.5 billion in annual revenue. Catalent is headquartered in Somerset, New Jersey.


Tel: +1 877-587-1835

(C) 2020 Electronic News Publishing, source ENP Newswire

Stocks mentioned in the article
ChangeLast1st jan.
CATALENT, INC. -2.80% 113 Delayed Quote.8.58%
All news about CATALENT, INC.
07/26CATALENT : Launches New OptiDose« Design Solution to Help Create Differentiated ..
07/22CATALENT : Biologics Launches New GPEx« Lightning Cell Line Expression Technolog..
07/21CATALENT : Plans Multi-Phase, $100 Million Expansion of Italian Facility to Incr..
07/21CATALENT : Plans $100 Million Expansion of Italian Vaccine Plant
07/21ASTRAZENECA : Catalent plans $100 million expansion at vaccine plant in Italy
07/21Catalent inc plans $100 mln expansion to add drug substance making capabiliti..
07/16INSIDER TRENDS : Catalent Insider Continues 90-Day Selling Trend
07/13CATALENT : Signs Agreement with JOS Pharmaceuticals to Develop Fast-Dissolve Zyd..
06/28CATALENT : Receives RoSPA Gold Award for Health and Safety Practices
06/25JOHNSON & JOHNSON : Wins European Nod For New COVID-19 Vaccine Production Facili..
More news
Financials (USD)
Sales 2021 3 944 M - -
Net income 2021 507 M - -
Net Debt 2021 1 977 M - -
P/E ratio 2021 38,3x
Yield 2021 -
Capitalization 19 249 M 19 249 M -
EV / Sales 2021 5,38x
EV / Sales 2022 4,84x
Nbr of Employees 13 900
Free-Float 99,5%
Duration : Period :
Catalent, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends CATALENT, INC.
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus BUY
Number of Analysts 13
Last Close Price 113,00 $
Average target price 136,70 $
Spread / Average Target 21,0%
EPS Revisions
Managers and Directors
John R. Chiminski Chairman & Chief Executive Officer
Alessandro Maselli President & Chief Operating Officer
Thomas P. Castellano Chief Financial Officer & Senior Vice President
Kay Schmidt Senior Vice President-Technical Operations
Julien Meissonnier Chief Scientific Officer & Vice President
Sector and Competitors
1st jan.Capi. (M$)
CATALENT, INC.8.58%18 594
JOHNSON & JOHNSON9.21%432 430
ROCHE HOLDING AG12.39%325 975
PFIZER, INC.13.58%218 198
NOVARTIS AG1.10%207 246